+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Variability in the pharmacokinetics of cyclophosphamide methotrexate and 5 fluorouracil cmf



Variability in the pharmacokinetics of cyclophosphamide methotrexate and 5 fluorouracil cmf



Proceedings of the American Association for Cancer Research Annual Meeting 33: 533




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034181829

Download citation: RISBibTeXText


Related references

Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer. Cancer ChemoTherapy and Pharmacology 33(6): 472-476, 1994

Clinical controlled trial in advanced breast cancer: CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CMF + T (cyclophosphamide, methotrexate, 5-fluorouracil, tamoxifen). CMEA Cooperative Treatment Group. Neoplasma 32(3): 381-387, 1985

Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer a randomized study of cyclophosphamide methotrexate 5 fluorouracil vs. cyclophosphamide methotrexate 5 fluorouracil plus tamoxifen. European Journal of Cancer and Clinical Oncology 21(3): 291-300, 1985

Doxorubicin and cyclophosphamide adjuvant chemotherapy is no more effective than cyclophosphamide, methotrexate, and 5-fluorouracil for premenopausal axillary lymph node positive breast cancer: There is no clear evidence that HER-2 status affects the relative effects of doxorubicin and cyclophosphamide vs cyclophosphamide, methotrexate and 5-fluorouracil in women with operable breast cancer. Evidence-Based Oncology 2(2): 83-86, 2001

Clinical controlled trial in advanced breast cancer cyclophosphamide methotrexate 5 fluorouracil vs. cyclophosphamide methotrexate 5 fluorouracil tamoxifen. Neoplasma 32(3): 381-388, 1985

Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin. Cancer 43(1): 51-59, 1979

Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF). European Journal of Cancer 38(8): 1081-1089, 2002

Pharmacokinetics of intravenous and oral cyclophosphamide in the presence of methotrexate and fluorouracil. Pharmaceutisch Weekblad. Scientific Edition 10(5): 200-206, 1988

Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model. Cancer Treatment Reports 71(12): 1267-1269, 1987

Cyclophosphamide phosphoramide mustard methotrexate and 5 fluorouracil pharmacokinetics during repeated combination therapy. Proceedings of the American Association for Cancer Research Annual Meeting 29: 192, 1988

A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Research and Treatment 3(2): 209-220, 1983

Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results. Drugs Under Experimental and Clinical Research 12(1-3): 143-145, 1986

Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer. Journal of Breast Cancer 14(3): 223-228, 2011

Cyclophosphamide methotrexate and fluorouracil cmf vs cyclophosphamide mitoxantrone and fluorouracil cnp in the treatment of metastatic breast cancer mbc a randomized trial. Journal of Cancer Research & Clinical Oncology 116(SUPPL PART 1): 393, 1990

Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan. Breast Cancer 17(3): 190-198, 2010